Wednesday, October 14, 2026
ExploreSearch
Via News
Via News Knowledge File

Micron Technology Inc

organization80% conf.·synced Oct 14, 2026

Memory and storage solutions manufacturer

60
sourced metrics
897
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
953.19USD
Oct 13, 2026reference only
Market Cap
1076526257602USD
Oct 13, 2026reference only
Price 52 Week Low
187.06USD
Oct 13, 2026reference only
Stock Return Ytd
202.2%
Oct 13, 2026reference only
Price 52 Week High
1213.56USD
Oct 13, 2026reference only
Shares Outstanding
1129393151.0shares
Jun 17, 2026reference only
Cash
24995000000.0USD
May 28, 2026reference only
Cost Of Revenue
6400000000.0USD
May 28, 2026reference only
Stockholders Equity
100724000000.0USD
May 28, 2026reference only
Revenue
41456000000.0USD
May 28, 2026reference only
Net Income
28243000000.0USD
May 28, 2026reference only
Gross Profit
35056000000.0USD
May 28, 2026reference only
Total Liabilities
33388000000.0USD
May 28, 2026reference only
Operating Income
33318000000.0USD
May 28, 2026reference only
Total Assets
134112000000.0USD
May 28, 2026reference only
Rd Expense
1316000000.0USD
May 28, 2026reference only
Eps
24.67USD_per_share
May 28, 2026reference only
Capex
5389000000.0USD
Nov 27, 2025reference only

Stated objectives

Achieve adjusted EPS of around $19.15 in Q3

source
target: 19.15 USD per share stated

Grow HBM market to $100 billion total addressable market

source
target: 100 billion USD by 2028-01-01 00:00:00stated

Begin production at Singapore HBM fab

source
by 2027-01-01 00:00:00stated

Begin DRAM production at retooled PSMC Taiwan fab

source
stated

Reach full production at Onondaga County, New York DRAM megafab complex

source
by 2030-01-01 00:00:00stated

Micron guided to Q1 FY2025 revenue between $12.2bn and $12.8bn

source
target: 12.2–12.8 billion USD stated

Micron guided to Q1 FY2025 adjusted EPS between $3.60 and $3.90

source
target: 3.60–3.90 USD EPS stated

$20 billion capital investment for fiscal 2026 including New York megafab and Idaho facility

source
target: 20 billion USD stated

Strategic focus on high-growth data center segments following exit from consumer products

source
stated

Complete first semiconductor fabrication facility outside Syracuse

source
by 2030-12-31 00:00:00stated

Relationship graph · 897 connections

Competes with
208
Supplies to
181
Covered by
162
Developed by
83
Invested in
50
Customer of
43
located in
31
Employs
30
has patent dispute with
Netlist

Via News coverage

Micron Has Doubled Its Spending on Chip Factories, and Wall Street Is Betting the AI Buildout Pays Off
October 9, 2026
Micron's Spending Has Roughly Doubled as AI Strains the Chip Supply, and Rivals Are Racing for Alternatives
October 8, 2026
Micron's Spending Doubled and Its Cash Pile Grew 2.5x. Other Stock Stories of the AI Boom Are Shakier
October 1, 2026
Nvidia's $950 Billion Week and a Memory Chip Rally Wall Street May Be Underrating
September 13, 2026
Nvidia's $950 Billion Korea Bet and a Wave of Chip Deals Collide With a Steep Semiconductor Sell-Off
August 16, 2026
Chip Stocks Sell Off Even as Nvidia Locks In Memory Supply and Washington Takes a Stake in GlobalFoundries
August 15, 2026
Intel +240%, AMD +112%: Global AI Inference Shift Leaves Nvidia Behind in 2026 Rally
May 12, 2026
Global Memory Chip Shortage Intensifies as AI Demand Triples Supply Requirements
March 8, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com